Menu Search
Equities

Sipai Health Technology Co, Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert
AX1:DUS

Sipai Health Technology Co, Ltd

Actions
  • Price (EUR)0.228
  • Today's Change-0.002 / -0.87%
  • Shares traded--
  • 1 Year change-62.62%
  • Beta--
Data delayed at least 15 minutes, as of Feb 18 2026 08:10 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Financials data is unavailable for this security.

Inc stmt in CNYIncome statement in CNYView more

Year on year Sipai Health Technology Co, Ltd's revenues fell -3.11% from 4.71bn to 4.57bn. This along with an increase in the cost of goods sold expense has contributed to a reduction in net income from a loss of 255.77m to a larger loss of 323.74m.
Gross margin9.74%
Net profit margin-10.75%
Operating margin-10.67%
Return on assets-15.51%
Return on equity-25.48%
Return on investment-28.98%
More ▼

Cash flow in CNYView more

In 2024, cash reserves at Sipai Health Technology Co, Ltd fell by 242.51m. Cash Flow from Investing was negative at 622.00k, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 59.45m for operations while cash used for financing totalled 184.06m.
Cash flow per share-0.5952
Price/Cash flow per share--
Book value per share1.50
Tangible book value per share1.46
More ▼

Balance sheet in CNYView more

Sipai Health Technology Co, Ltd uses little debt in its capital structure as supported by a debt to capital ratio of 2.52%.
Current ratio1.78
Quick ratio1.67
Total debt/total equity0.0248
Total debt/total capital0.0252
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.